TABLE 2.

Ongoing Trials of Immunotherapy in Cervical Cancer (Original table)

	NTC	Setting	Phase	Agents	n	Estimated Completion Date
CHECKPOINT INHIBITORS
GOG 3016/ENGOT-cx9	NTC03257267	Second-line metastatic	Phase III	Cemiplimab Chemotherapy (Investigator’s choice)	534	June 2023
CHECKPOINT INHIBITORS + RADIATION
NiCOL	NCT03298893	Locally advanced untreated cervical cancer	Phase I	Cisplatin + WPRT + Nivolumab	21	May, 2022
UVA-LACC-PD201	NCT02635360	Locally advanced untreated cervical cancer	Randomized phase I	Cisplatin + WPRT + Pembrolizumab Cisplatin + WPRT followed by Pembrolizumab	88	May, 2021
GOG-9929	NCT01711515	Node (+) cervical cancer	Phase I	Cisplatin + WPRT + Ipiilimumab	34	June, 2017
NRG GY017/NCI-2018-02791	NCT03738228	Locally advanced cervical cancer	Randomized Phase I	Cisplatin + WPRT + atezolizumab Atezolizumab followed by WPRT + cisplatin	40	November, 2021
CALLA	NCT03830866	Locally advanced untreated cervical cancer	Phase III	Cisplatin + WPRT + durvalumab cisplatin + WPRT + placebo	714	April, 2024
ATEZOLACC	NCT03612791	Locally advanced untreated cervical cancer	Randomized Phase II	Cisplatin + WPRT Cisplatin + WPRT + atzezolizumab	190	July, 2022
KEYNOTE-826/ MK-3475-826	NCT03635567	First-line metastatic	Randomized Phase III	Paclitaxel + platinum ± bevacizumab followed by Pembrolizumab Paclitaxel + platinum ± bevacizumab followed by placebo	600	November, 2022
BEATcc/GOG-3030/ENGOT Cx10/JGOG 1084/GEICO 68-C	NCT03556839	Recurrent/Metastatic		Paclitaxel + cisplatin + bevacizumab followed by atezolizumab Paclitaxel + cisplatin + bevacizumab followed by placebo	404	July, 2023
MCC-19662/ML40521	NCT03614949	First-line metastatic	Phase II	Radiation + atezolizumab	26	December, 2022
PD-1 and CTLA-4 COMBINATIONS
C-550-01	NCT03495882	Second-line metastatic	Phase I/II	AGEN0234 + AGEN1884	150	March 2023
RaPiDS/GOG-3028/C-750-01	NCT03894215	Second-line metastatic	Randomized Phase II	AGEN0234 ± AGEN 1884	200	August, 2023

WPRT - whole pelvic radiation therapy